CGC Canopy Growth (CGC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001737927
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
73
13F, latest reported quarter
What the filings say about CGC
Insiders, 180 days
-$325.2K net sold
7 sellers · 0% of sales under a 10b5-1 plan
Canopy Growth insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Canopy Growth Corp insiders sold a net $325.2K of stock across 78 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 26, 2026.
- The trade is 2.2% of the 143,421 shares held after it.
- 4 other insiders sold within 30 days.
- 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ATKINS M SHAN sold about $2.9K of CGC on Sep 28, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 26, 2026.
- The trade is 11.8% of the 189,479 shares held after it.
- 4 other insiders sold within 30 days.
- 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lazzarato David Angelo sold about $20.7K of CGC on Sep 28, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 26, 2026.
- The trade is 2.2% of the 142,031 shares held after it.
- 4 other insiders sold within 30 days.
- 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BAYERN JOSEPH sold about $2.9K of CGC on Sep 28, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 26, 2026.
- The trade is 11.3% of the 131,495 shares held after it.
- 4 other insiders sold within 30 days.
- 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Yanofsky Theresa sold about $13.8K of CGC on Sep 28, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 24, 2026.
- The trade is 4.4% of the 588,412 shares held after it.
- 5 other insiders sold within 30 days.
- 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Stewart Thomas Carlton sold about $24.0K of CGC on Sep 17, 2026; 5 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.78 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$325.2K over 180 days
-$87.2K over 90 days
below 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
73 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-26) · 13.0 days to cover · settled 2026-09-30
more than 58% of Pharma & Biotech
What changed in the last 30 days
Sep 30Director Lazzarato David Angelo sold $20.7K (Sep 28)
Sep 30Director Yanofsky Theresa sold $13.8K (Sep 28)
Sep 30Director ATKINS M SHAN sold $2.9K (Sep 28)
Sep 30Director BAYERN JOSEPH sold $2.9K (Sep 28)
Watch CGC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-49.4%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CGC: institutional holders (13F)
13F holdings, latest reported quarter
9,189,630 sh
$8.7M
27 sh
$6.7M
1,946,294 sh
$1.8M
1,847,500 sh
$1.8M
1,562,808 sh
$1.5M
Congress trades in CGC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CGC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CGC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Amplify Alternative Harvest ETF
$8.7M position · as of 2026-06-30
7.9%
AdvisorShares Pure Cannabis ETF
$275.2K position · as of 2026-06-30
0.8%
USA Mutuals Vice Fund
$285.0K position · as of 2026-06-30
0.6%
Lazard US Systematic Small Cap Equity ETF
$95.9K position · as of 2026-06-30
0.1%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF
$134.4K position · as of 2026-06-30
0.0%
LVIP Dimensional International Core Equity Fund
$6.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · David Klein
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$6.5M
$534.3K
$2.3M
-88%
-80%
2021
$4.5M
-$27.9M
$2.0M
-54%
-37%
2020
$2.8M
$36.1M
$1.4M
+97%
+88%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $325.2K sold by insiders over 180 days, 73 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CGC financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$358.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CGC
| FY Mar 2026 | $346.8M |
| FY Mar 2025 | $314.0M |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | $582.2M |
| Jun 2026 | $100.4M |
| Mar 2026 | $84.7M |
| Dec 2025 | $90.4M |
| Sep 2025 | $83.0M |
| Jun 2025 | $88.7M |
| Mar 2025 | $78.0M |
| Dec 2024 | $86.2M |
| Sep 2024 | $74.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-44.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CGC
| FY Mar 2026 | -54.5% |
| FY Mar 2025 | -112.7% |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | -42.6% |
| Jun 2026 | -14.5% |
| Mar 2026 | -95.4% |
| Dec 2025 | -64.5% |
| Sep 2025 | -6.0% |
| Jun 2025 | -50.5% |
| Mar 2025 | -52.7% |
| Dec 2024 | -113.7% |
| Sep 2024 | -147.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$83.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CGC
| FY Mar 2026 | -$69.1M |
| FY Mar 2025 | -$176.6M |
| FY Mar 2024 | -$285.4M |
| FY Mar 2023 | -$566.7M |
| FY Mar 2022 | -$582.5M |
| Jun 2026 | -$25.7M |
| Mar 2026 | -$19.3M |
| Dec 2025 | -$19.0M |
| Sep 2025 | -$19.2M |
| Jun 2025 | -$11.6M |
| Mar 2025 | -$36.2M |
| Dec 2024 | -$28.2M |
| Sep 2024 | -$56.4M |
At each fiscal year end
Single quarter
Debt to equity
0.35x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CGC
| FY Mar 2026 | 0.33x |
| FY Mar 2025 | 0.64x |
| FY Mar 2024 | 1.49x |
| FY Mar 2023 | 1.72x |
| FY Mar 2022 | 0.42x |
| Jun 2026 | 0.35x |
| Mar 2026 | 0.33x |
| Dec 2025 | 0.30x |
| Sep 2025 | 0.32x |
| Jun 2025 | 0.62x |
| Mar 2025 | 0.64x |
| Dec 2024 | 0.79x |
| Sep 2024 | 1.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.33x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CGC
| FY Mar 2026 | -0.27x |
| FY Mar 2025 | -0.55x |
| FY Mar 2024 | -0.47x |
| FY Mar 2023 | -0.43x |
| FY Mar 2022 | -0.36x |
| Jun 2026 | -0.33x |
| Mar 2026 | -0.27x |
| Dec 2025 | -0.35x |
| Sep 2025 | -0.39x |
| Jun 2025 | -0.42x |
| Mar 2025 | -0.55x |
| Dec 2024 | -0.35x |
| Sep 2024 | -0.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-27.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CGC
| FY Mar 2026 | -32.1% |
| FY Mar 2025 | -80.5% |
| FY Mar 2024 | -90.8% |
| FY Mar 2023 | -111.6% |
| FY Mar 2022 | -7.0% |
| Jun 2026 | -27.2% |
| Mar 2026 | -32.1% |
| Dec 2025 | -22.9% |
| Sep 2025 | -31.9% |
| Jun 2025 | -62.1% |
| Mar 2025 | -80.5% |
| Dec 2024 | -53.7% |
| Sep 2024 | -67.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-15.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CGC
| FY Mar 2026 | -18.6% |
| FY Mar 2025 | -31.9% |
| FY Mar 2024 | -28.1% |
| FY Mar 2023 | -60.2% |
| FY Mar 2022 | -4.0% |
| Jun 2026 | -15.8% |
| Mar 2026 | -18.6% |
| Dec 2025 | -13.1% |
| Sep 2025 | -16.4% |
| Jun 2025 | -26.7% |
| Mar 2025 | -31.9% |
| Dec 2024 | -23.3% |
| Sep 2024 | -27.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CGC
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-18.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CGC
| FY Mar 2026 | -18.2% |
| FY Mar 2025 | -13.2% |
| FY Mar 2024 | -17.6% |
| FY Mar 2023 | n/a |
| FY Mar 2022 | -17.1% |
| Jun 2026 | -18.6% |
| Mar 2026 | -18.2% |
| Dec 2025 | -8.3% |
| Sep 2025 | -8.7% |
| Jun 2025 | -12.0% |
| Mar 2025 | -13.2% |
| Dec 2024 | -19.0% |
| Sep 2024 | -20.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CGC
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$186.2M
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CGC
| FY Mar 2026 | $227.3M |
| FY Mar 2025 | $324.1M |
| FY Mar 2024 | $1.2B |
| FY Mar 2023 | $9.3B |
| FY Mar 2022 | $30.6B |
| Jun 2026 | $304.6M |
| Mar 2026 | $227.3M |
| Dec 2025 | $243.8M |
| Sep 2025 | $280.3M |
| Jun 2025 | $395.0M |
| Mar 2025 | $324.1M |
| Dec 2024 | $568.3M |
| Sep 2024 | $734.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-29.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield CGC
| FY Mar 2026 | -19.3% |
| FY Mar 2025 | -131.9% |
| FY Mar 2024 | -36.3% |
| FY Mar 2023 | -6.5% |
| FY Mar 2022 | -1.9% |
| Jun 2026 | -20.8% |
| Mar 2026 | -19.3% |
| Dec 2025 | -22.1% |
| Sep 2025 | -27.2% |
| Jun 2025 | -58.6% |
| Mar 2025 | -131.9% |
| Dec 2024 | -56.3% |
| Sep 2024 | -41.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CGC
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $346.8M | $314.0M | $343.9M | $450.9M |
| Gross profit | $69.7M | $79.5M | $80.9M | -$63.5M |
| Operating income | -$161.7M | -$117.1M | -$228.7M | -$2.6B |
| Net income | -$189.0M | -$354.0M | -$526.0M | -$2.4B |
| EPS (diluted) | -0.88 | -4.73 | -9.27 | -70.69 |
| Operating cash flow | -$63.8M | -$165.8M | -$281.9M | -$557.5M |
| Cash | $364.7M | $113.8M | $170.3M | $667.7M |
| Long-term debt | $217.1M | $299.8M | $493.3M | $750.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
CGC Stock Sonar score 5/7 axes
Find similar shapesCompareCGC ranks highest on profitability (71st percentile) and institutional and government (57th), and lowest on insider conviction (23rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CGC filings, in plain words
Are Canopy Growth insiders buying or selling CGC?
In the 180 days to 2026-10-28, Canopy Growth insiders were net sellers, a net $325.2K across purchases and sales reported on Form 4, by 7 sellers.
Read the full summary
In the 180 days to 2026-10-28, Canopy Growth insiders were net sellers of CGC, a net $325.2K across purchases and sales reported on Form 4 by 7 sellers. None of the 14 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
